Thermo Fischer Scientific Inc., the world leader in serving science, has signed a definitive agreement to acquire all shares in the company owning Phadia AB, a global leader in allergy and autoimmunity diagnostics, from the private equity firm Cinven and Phadia AB's management, for EUR 2.47 billion in cash. The agreement between the parties is signed and completion of the transaction is conditional upon inter alia approval from relevant competition authorities. Setterwalls has assisted Phadia AB and the management of Phadia AB in connection with the transaction.
Setterwalls' team consisted of Emine Lundkvist, Karl-Johan Grundström, Anders Söderlind and Carl Friberg.